Opioid maintenance treatment

PreclinicalSmall molecule

Opioid maintenance treatment is one of 21 small molecule programs targeting Opioid Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid DependenceActive, not recruiting

Opioid DependencePreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Opioid Dependence

#DrugCompanyPhaseTrials

Keppra

Epidiolex

Victoza

Actos

Narcan

Oxycontin

Ketalar

AAultman Health Foundation

Pitocin

Selincro

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid Dependence1 trial

Effects on Mortality and Clinical Course of a Patient's Choice Model for Opioid Maintenance Treatment for Opioid Dependence - Evaluation of a System Enabling a Large Expansion of Treatment Providers and Treatment Access

Unknown status·RRegion Skane··NCT05678036·2,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Opioid maintenance treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Opioid maintenance treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Opioid maintenance treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Skane company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRegion Skane

Opioid maintenance treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid Dependence1 trial

References

Drug Info

Quick Facts

Related News